CA
DNLI icon

Clearstead Advisors’s Denali Therapeutics DNLI Stock Holding History

Clearstead Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59K Sell
62
-737,928
-100% -$15.2M ﹤0.01% 2554
2026
Q1 		$14.2M Buy
+737,990
New +$14.7M 0.13% 133

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Advisors's DNLI Position: Q2 2026 in Review

Clearstead Advisors reduced its Denali Therapeutics (DNLI) stake by 100% in Q2 2026, selling an estimated $15.2M and leaving 62 shares worth $1.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2554.

Clearstead Advisors first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. The position peaked at $14.2M in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Clearstead Advisors held 62 shares of Denali Therapeutics worth $1.59K as of Q2 2026.
  • Clearstead Advisors sold 737,928 Denali Therapeutics shares in Q2 2026, an estimated $15.2M.
  • Denali Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2554 holding.
  • Clearstead Advisors first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Clearstead Advisors's Denali Therapeutics position peaked at $14.2M in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.